布鲁顿的氨酸激酶 - 免疫媒介炎症疾病的新目标?
1Translational and Clinical Research Institute, Faculty of Medical Sciences, Framlington Place, Newcastle upon Tyne NE2 4HH, UK; Musculoskeletal Unit, Freeman Hospital, Freeman Road, Newcastle upon Tyne NE7 7DN, UK.
Seminars in arthritis and rheumatism
|March 1, 2025
概括
布鲁顿的氨酸激酶抑制剂 (BTKi) 对诸如Sjogren综合征和多发性硬化症等自身免疫性疾病有前途,但疗效各不相同. 新的BTKi提供了更好的安全性,尽管在理解可变治疗反应方面仍然存在挑战.
科学领域:
- 免疫学 免疫学 免疫学
- 药理学 药理学 是一个学科.
- 细胞生物学 细胞生物学
背景情况:
- 布鲁顿的氨酸激酶 (BTK) 对于B细胞和髓状细胞的信号传递至关重要.
- 由于BTK缺乏,导致X相关的AGAMMAGLOBULINEMIA;BTK抑制剂 (BTKi) 治疗B细胞恶性瘤.
- 对于自身免疫和炎症性疾病,BTKi被探索.
研究的目的:
- 审查BTK抑制剂 (BTKi) 在各种免疫媒介疾病中的疗效和安全性.
- 探索不同条件下BTKi的可变反应的原因.
主要方法:
- 关于BTK抑制剂在类风湿性,神经性,皮肤性和过敏性疾病中的研究的文献综述.
- 对第一代和第二代BTKi.安全概况的分析.
- 讨论影响BTKi疗效的因素,包括疾病特异性途径.
主要成果:
- BTKi在类风湿性关节炎和狼中表现出有限的疗效,但在Sjogren综合征中具有潜力.
- 有针对多发性硬化症,慢性自发性疹和pemphigus vulgaris的积极数据.
- 第一代BTKi具有显著的毒性;第二代抑制剂已经改善了安全性,但剂量限制性毒性仍然存在.
结论:
- BTK 抑制剂是针对特定免疫媒介疾病的新兴疗法,临床成功程度各不相同.
- 了解疾病特异性的B细胞和髓状细胞通路依赖性是优化BTKi治疗的关键.
- 目前正在进行的研究旨在完善BTKi的安全性和有效性,以便在更广泛的临床应用中.
相关概念视频
Transducer Mechanism: Enzyme-Linked Receptors
2.3K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.3K
Receptor Tyrosine Kinases
12.1K
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
12.1K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
The JAK-STAT Signaling Pathway
8.6K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.6K
Autoimmune Disorders
377
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
Concept and Mechanism of Autoimmune Diseases
The immune...
377
Enzyme-linked Receptors
76.9K
Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
76.9K


